The Valley Desk

ArticleJournal of health economics and outcomes researchPublished

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of health economics and outcomes research
Published
Subject terms
Indirect Treatment Comparison; Matching-adjusted Indirect Comparison; Erdafitinib; Enfortumab Vedotin; Locally Advanced Unresectable Metastatic Urothelial Carcinoma
PubMed ID
39267886
PubMed Central ID
PMC11392482
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal